Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
01Psyence has secured a partnership with a leading Canadian university for a groundbreaking clinical trial, potentially increasing its market visibility and credibility.
02Recent studies show a 75% efficacy rate of Psyence's lead compound in treating PTSD, which could lead to accelerated regulatory approval.
03An increase in public interest and investment in mental health solutions could drive demand for Psyence's products, with a potential market size growth of 30% by 2028.
04Mental health treatment innovation
05Psychedelic therapy mainstreaming
06Regulatory approvals for clinical trials of psychedelic compounds
07Partnership announcements with major healthcare institutions
08Market sentiment regarding the acceptance of psychedelics in mainstream medicine
